(18 Apr 2021) Otilimab- demonstrated a substantial benefit in severe COVID patients
A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR) https://www.medrxiv.org/content/10.1101/2021.04.14.21255475v1 NCT04376684- Overall, 806 patients were randomized (1:1); 71% of patients receiving otilimab were alive and free of respiratory failure at Day 28 versus 67% receiving placebo, although this did… Continue reading "(18 Apr 2021) Otilimab- demonstrated a substantial benefit in severe COVID patients"